Henlius Reports Sustained Growth in Revenues and Profits for 2025

Henlius, a prominent player in the biopharmaceutical industry, recently unveiled its annual results for 2025, showcasing remarkable performance that demonstrates the company's resilience and innovation. This year marks the third consecutive year of profitability, a significant milestone since Henlius first achieved annual profits back in 2023.

During this reporting period, the company achieved total revenues of 6.67 billion RMB, reflecting a robust year-on-year growth of 16.5%. Henlius reported a net profit of 827 million RMB, highlighting its successful strategies and operational efficiencies. Notably, the company's investment in Research and Development (R&D) reached 2.49 billion RMB, an increase of 35.4% compared to the previous year. This continued commitment to innovation has allowed Henlius to achieve a pre-R&D profit of 2.34 billion RMB, which is 26.2% higher than the prior year.

In 2025, Henlius has successfully strengthened its global growth momentum, with total product sales reaching 5.77 billion RMB, significantly driven by increasing sales of its main products, serplulimab (marketed as Hetronifly® in Europe) and HANQUYOU (trastuzumab, marketed as HERCESSI™ in the USA and Zercepac® in Europe). The company also benefited from rapid milestone payments stemming from strategic alliances, which have helped solidify its international expansion plans. Notably, sales from products outside of China surpassed 200 million RMB in 2025, effectively doubling the figures from the previous year. The overall product profit climbed to 93.9 million RMB during this time.

To date, Henlius has obtained approvals for 10 products across 60 countries and regions, including 4 FDA approvals in the U.S. and 4 from the European Commission, benefiting over a million patients globally. One standout product, serplulimab, continued to yield impressive commercial success worldwide, recording global sales of 1.49 billion RMB, which represents a 13.7% year-on-year increase. In this period, global sales for Henlius's breast cancer products reached 3.27 billion RMB, underscoring the company's impactful portfolio.

Henlius launched the two doses of HLX14 (denosumab) commercially in the U.S., Germany, Spain, and the United Kingdom, generating sales revenue of 9.8 million RMB during the report period. The company remains focused on advancing its innovative product pipeline, with key assets in critical clinical phases, including dulpatatug (HLX22, a new anti-HER2 monoclonal antibody) and HLX43 (a PD-L1 antibody-drug conjugate).

Thanks to its robust integrated capabilities spanning R&D, clinical operations, regulatory affairs, manufacturing, and commercialization, Henlius is accelerating its transition towards a global biopharmaceutical model rooted in China. Looking ahead, Henlius is committed to delivering high-quality biological products to patients worldwide, further solidifying its presence in the pharmaceutical landscape.

In conclusion, 2025 has proven to be another benchmark year for Henlius, not only in terms of financial growth but also in its unwavering dedication to product innovation and global outreach. As the company continues to thrive, it sets ambitious goals for the future, aiming to extend its support to patients around the globe with its advanced biopharmaceutical solutions.